Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00589420 | Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy | completed | Phase 2 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 17, 2022 | clinicaltrials |
| NCT03101046 | Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic(TACTIK) | completed | Phase 2 | 40 | UNICANCEROTHER | 1 | Feb 10, 2022 |
| clinicaltrials |
| NCT02601014 | Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7(STARVE-PC) | completed | Phase 2 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 3, 2022 | clinicaltrials |
| NCT01377753 | MR Image Guided Therapy in Prostate Cancer | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2022 | clinicaltrials |
| NCT01759836 | Impact of Adjuvant Statin Therapy in Patients Who Underwent Radical Prostatectomy for Locally Advanced Prostate Cancer | completed | Phase 2 | 364 | Asan Medical CenterOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT02673151 | 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment | completed | Phase 2 / Phase 3 | 61 | Andrei IagaruOTHER | 1 | Jan 13, 2022 | clinicaltrials |
| NCT02849990 | A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy | completed | Phase 2 | 22 | University of WashingtonOTHER | 1 | Jan 13, 2022 | clinicaltrials |
| NCT02001623 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 195 | Seagen Inc.INDUSTRY | 5 | Dec 29, 2021 | clinicaltrials |
| NCT00545766 | Vinflunine in Hormone Refractory Prostate Cancer (HRPC) | completed | Phase 2 | 41 | SCRI Development Innovations, LLCOTHER | 1 | Dec 16, 2021 | clinicaltrials |
| NCT02711956 | A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 75 | Zenith EpigeneticsINDUSTRY | 1 | Nov 30, 2021 | clinicaltrials |
| NCT02737332 | A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer(STAAR) | completed | Phase 2 | 53 | Sun Pharmaceutical Industries LimitedINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT01751451 | 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy | completed | Phase 2 | 124 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 19, 2021 | clinicaltrials |
| NCT02962284 | One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™ | completed | Phase 2 | 20 | Sun Pharmaceutical Industries LimitedINDUSTRY | 0 | Nov 19, 2021 | clinicaltrials |
| NCT02280317 | Dose Finding Safety Study of VAL201 in Cancer Patients(VAL201-001) | completed | Phase 1 / Phase 2 | 12 | ValiRx PlcINDUSTRY | 0 | Nov 8, 2021 | clinicaltrials |
| NCT04555343 | Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention | completed | Phase 1 / Phase 2 | 14 | Fraser HealthOTHER | 1 | Nov 5, 2021 | clinicaltrials |
| NCT03245736 | Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. | completed | Phase 2 | 5 | Seagen Inc.INDUSTRY | 2 | Nov 4, 2021 | clinicaltrials |
| NCT01252693 | International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer | completed | Phase 2 | 203 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Oct 5, 2021 | clinicaltrials |
| NCT04050215 | 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer | completed | Phase 2 | 937 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 30, 2021 | clinicaltrials |
| NCT01105130 | L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors | completed | Phase 2 | 140 | Wake Forest University Health SciencesOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT01535040 | Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking | completed | Phase 2 | 130 | Wake Forest University Health SciencesOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT02499497 | A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer | completed | Phase 2 | 114 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT03062254 | Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy | completed | Phase 2 | 14 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Sep 21, 2021 | clinicaltrials |
| NCT02346578 | Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy. | completed | Phase 2 | 104 | Taro Iguchi, MD, PHDOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT01804465 | Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer | completed | Phase 2 | 50 | University of California, San FranciscoOTHER | 1 | Aug 18, 2021 | clinicaltrials |
| NCT02981368 | Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer(OSPREY) | completed | Phase 2 / Phase 3 | 385 | Progenics Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 9, 2021 | clinicaltrials |
| NCT00214136 | Intensity Modulated Radiation Therapy (IMRT) Radiotherapy for Treating Prostate Pelvic Nodes | completed | Phase 2 | 30 | University of Wisconsin, MadisonOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT01505868 | Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 170 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT02463799 | Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC | completed | Phase 2 | 36 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT02867020 | Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels | completed | Phase 2 | 128 | Latin American Cooperative Oncology GroupOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT00667862 | Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer | completed | Phase 2 | 35 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 21, 2021 | clinicaltrials |
| NCT01706458 | Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer | completed | Phase 2 | 18 | University of Wisconsin, MadisonOTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT03361969 | Evaluation of Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist. | completed | Phase 2 | 63 | Pantarhei Oncology B.V.OTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT01254513 | Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients(GERICO10) | completed | Phase 2 | 66 | UNICANCEROTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT02229734 | Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2(FASTR-2) | completed | Phase 2 | 60 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT02559115 | 68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer | completed | Phase 2 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT01503229 | Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 32 | University of WashingtonOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT01540071 | Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer | completed | Phase 2 | 38 | Io TherapeuticsINDUSTRY | 1 | May 14, 2021 | clinicaltrials |
| NCT01728233 | Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis(HER-Uro01) | completed | Phase 2 | 32 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT00087165 | GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer | completed | Phase 2 | 22 | University Health Network, TorontoOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT01868386 | Shorter Duration Radiotherapy to Treat Prostate Cancer After Removal of the Prostate(HypoFX) | completed | Phase 1 / Phase 2 | 32 | Timothy Showalter, MDOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT02987829 | Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients | completed | Phase 1 / Phase 2 | 72 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Apr 23, 2021 | clinicaltrials |
| NCT02046837 | An Exercise Trial and Economic Analysis in Men With Prostate Cancer(ADT Ex RCT) | completed | Phase 2 | 59 | University Health Network, TorontoOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT00350051 | ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer | completed | Phase 2 | 53 | BayerINDUSTRY | 2 | Apr 8, 2021 | clinicaltrials |
| NCT00737893 | Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy(ERECT) | completed | Phase 2 | 56 | Johns Hopkins UniversityOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT02552121 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 33 | Seagen Inc.INDUSTRY | 5 | Apr 8, 2021 | clinicaltrials |
| NCT01317199 | Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer | completed | Phase 1 / Phase 2 | 143 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT02142608 | A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer | completed | Phase 1 / Phase 2 | 19 | Bracco Diagnostics, IncINDUSTRY | 2 | Mar 29, 2021 | clinicaltrials |
| NCT01468532 | Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 18 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 25, 2021 | clinicaltrials |
| NCT01615120 | Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer | completed | Phase 2 | 77 | GTxINDUSTRY | 1 | Mar 24, 2021 | clinicaltrials |
| NCT01748500 | Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 21 | University Health Network, TorontoOTHER | 1 | Mar 23, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Feb 17, 2022source: clinicaltrials